Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Michael L. Bernard"'
Publikováno v:
HeartRhythm Case Reports, Vol 3, Iss 10, p 493 (2017)
Externí odkaz:
https://doaj.org/article/743118cbaf104922bf8f940828e50afd
Autor:
Joshua Aymond, Walter J. Hoyt, Patricia E. Thomas, Thomas Young, Daniel P. Morin, Michael L. Bernard
Publikováno v:
HeartRhythm Case Reports. 8:776-780
Autor:
Elaine Huang, Michael L. Bernard, A. Elise Hiltbold, Sammy Khatib, Glenn M. Polin, Paul A. Rogers, Paari Dominic, Daniel P. Morin
Publikováno v:
Journal of Cardiovascular Electrophysiology. 33:2375-2381
Heart failure (HF) is a major cause of morbidity and mortality, with nearly half of all HF-related deaths resulting from sudden cardiac death (SCD), most often from an arrhythmic event. The pathophysiologic changes that occur in response to the hemod
Autor:
Donald D. Chang, Peter G. Pantlin, Francis A. Benn, T. Ryan Gullatt, Michael L. Bernard, A. Elise Hiltbold, Sammy Khatib, Glenn M. Polin, Paul A. Rogers, Cruz Velasco‐Gonzalez, Daniel P. Morin
Publikováno v:
Journal of Cardiovascular Electrophysiology.
Autor:
Joshua D. Aymond, Thomas Gullatt, Michael L. Bernard, Aimee E. Hiltbold, Sammy Khatib, Glenn M. Polin, Paul Rogers, Michael R. Castine, Paari Dominic, Daniel P. Morin
Publikováno v:
Heart Rhythm. 20:S69-S70
Autor:
Paul A. Rogers, Francis Benn, Glenn M. Polin, A. Elise Hiltbold, Cody M. Williams, Sammy Khatib, Michael L. Bernard, Sana M. Al-Khatib, Daniel P. Morin
Publikováno v:
Progress in Cardiovascular Diseases. 66:80-85
Atrial Fibrillation (AF) and heart failure (HF) with reduced ejection fraction (HFrEF) frequently coexist, resulting in significant morbidity and mortality. Therapeutic options for patients with AF and HFrEF are limited due to few antiarrhythmic drug
Autor:
Paul A. Rogers, Sudarone Thihalolipavan, Daniel P. Morin, Ronald Chong-Yik, Sammy Khatib, Yoaav S Krauthammer, Glenn M. Polin, Michael L. Bernard
Publikováno v:
EP Europace. 22:1044-1053
Aims Evidence links markers of systemic inflammation and heart failure (HF) with ventricular arrhythmias (VA) and/or death. Biomarker levels, and the risk they indicate, may vary over time. We evaluated the utility of serial laboratory measurements o
Autor:
Todd M. Rosenthal, Daniel P. Morin, Freddy M. Abi-Samra, Sammy Khatib, Paul A. Rogers, Thomas Middour, Robert M. Bober, Glenn M. Polin, Michael L. Bernard
Publikováno v:
Journal of Cardiovascular Electrophysiology. 31:1137-1146
Sudden cardiac death is a substantial cause of mortality in patients with cardiomyopathy, but evidence supporting implantable cardioverter-defibrillator (ICD) implantation is less robust in nonischemic cardiomyopathy (NICM) than in ischemic cardiomyo
Autor:
Michael L. Bernard, Robert M. Bober, Glenn M. Polin, Sammy Khatib, Paul A. Rogers, Daniel P. Morin, Peter G. Pantlin
Publikováno v:
Journal of Cardiovascular Electrophysiology
Background Class 1C antiarrhythmic drugs (AADs) are effective first‐line agents for atrial fibrillation (AF) treatment. However, these agents commonly are avoided in patients with known coronary artery disease (CAD), due to known increased risk in
Publikováno v:
The Ochsner Journal
Background: Posterior wall isolation for recurrent atrial arrhythmia is a commonly used technique to achieve long-term freedom from atrial fibrillation. Despite the widespread use of posterior wall isolation, its long-term effects on left atrial func